Hanmi R&D becomes stronger through cooperation with partners.

^LAPSGlucagon Combo is a novel drug candidate consisting of efpegerglucagon (^LAPSGlucagon analog) and efpeglenatide (^LAPSExd4 analog).
Although the efficacy of glucagon-like protein-1 receptor agonist (GLP-1RA) is well-established for obesity and T2DM, more efforts are still required to close the efficacy gap with bariatric surgery. Recent advances demonstrate the beneficial effects of glucagon (GCG) receptor activation on energy expenditure, lipid metabolism, and cardiorenal protection in addition to satiety control. Therefore, the combination of GCG and GLP-1 not only enhances body weight loss barely achieved by current therapies, but also expands its the therapeutic utility to include various cardio-metabolic diseases.

In nonclinical studies, the therapeutic benefits of ^LAPSGlucagon Combo were well demonstrated in animal models of obesity, dyslipidemia, MASH/fibrosis, or chronic kidney disease. In addition to GLP toxicology package for each mono, repeat-dose toxicology studies of ^LAPSGlucagon Combo were completed to support its seamless clinical development. Based on these results, Hanmi expects that by optimizing the composition between efpegerglucagon and efpeglenatide, ^LAPSGlucagon Combo could be a next-generation anti-obesity medication with differentiated CVRM (cardiovascular, renal and metabolism) benefits.